Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand

BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.

Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts

Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.

Urmimala Biswas headshot

Medtronic Stock Moves Above 50-Day SMA: Should You Buy MDT?

Medtronic's (MDT) stock finally breaking above its 50-day SMA can be a piece of good news for investors, signaling an uptrend.

Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat

Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.

QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash

QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.

Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y

Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.

Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Neogen (NEOG) Q4 Earnings Miss Estimates, Margins Crash

Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.

Integra's (IART) Q2 Earnings and Revenues Top, Margins Down

Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.

Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year

Philips' (PHG) second-quarter results benefit from strong momentum across the Diagnosis & Treatment, Connected Care and Personal Health businesses.

Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet

The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise

Hologic (HOLX) delivers strong performances across all its franchises in the third quarter of fiscal 2024.

Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up

Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.

ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand

ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.

Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down

Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.

The Zacks Analyst Blog Highlights SAP, Abbott Laboratories, Citigroup, Team and Vaso

SAP, Abbott Laboratories, Citigroup, Team and Vaso are part of the Zacks top Analyst Blog.

Align Technology (ALGN) Beats on Q2 Earnings, Lowers '24 Sales View

Align Technology's (ALGN) records second-quarter 2024 revenue growth across all regions. This was mostly due to a robust performance by the Imaging Systems & CAD/CAM Services business segment.

Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash

Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.

Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand

Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.

Sheraz Mian headshot

Top Analyst Reports for SAP, Abbott Laboratories & Citigroup

Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Abbott Laboratories (ABT) and Citigroup Inc. (C), as well as two micro-cap stocks Team, Inc. (TISI) and Vaso Corporation (VASO).

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook

Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.

Jobless Claims Increased More Than Expected

Jobless Claims Increased More Than Expected

Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand

Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.